Eli Lilly (LLY)
(Delayed Data from NYSE)
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Eli Lilly (LLY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1,032.96 | $1,250.00 | $640.00 | 24.49% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Eli Lilly comes to $1,032.96. The forecasts range from a low of $640.00 to a high of $1,250.00. The average price target represents an increase of 24.49% from the last closing price of $829.74.
Analyst Price Targets (24)
Broker Rating
Eli Lilly currently has an average brokerage recommendation (ABR) of 1.19 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 1.19 a month ago based on 24 recommendations.
Of the 24 recommendations deriving the current ABR, 21 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 87.5% and 4.17% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 4.17%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 22 | 22 | 21 | 21 | 20 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.18 | 1.18 | 1.19 | 1.19 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/31/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
10/31/2024 | UBS | Trung Huynh | Strong Buy | Strong Buy |
10/31/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
10/17/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
10/9/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
9/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/12/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
9/6/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
9/5/2024 | Evercore Partners | Umer Raffat | Not Available | Hold |
8/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/14/2024 | Daiwa America | Narumi Nakagiri | Strong Buy | Strong Buy |
8/9/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
8/8/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
8/5/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
7/24/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/2/2024 | Berenberg Bank | Kerry Holford | Strong Buy | Strong Buy |
5/30/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
5/14/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
4/11/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.18 |
ABR (Last week) | 1.18 |
# of Recs in ABR | 25 |
Average Target Price | $1,026.50 |
LT Growth Rate | 20.00% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 60 of 252 |
Current Quarter EPS Est: | 5.49 |
LLY FAQs
Eli Lilly and Company (LLY) currently has an average brokerage recommendation (ABR) of 1.18 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms.
The average price target for Eli Lilly and Company (LLY) is $#######. The current on short-term price targets is based on 8 reports.
The forecasts for Eli Lilly and Company (LLY) range from a low of $640 to a high of $1250. The average price target represents a increase of $25.35 from the last closing price of $818.93.
The current UPSIDE for Eli Lilly and Company (LLY) is 25.35%
Based on short-term price targets offered by 24 analysts, the average price target for Eli Lilly comes to $1,032.96. The forecasts range from a low of $640.00 to a high of $1,250.00. The average price target represents an increase of 24.49% from the last closing price of $829.74.